Clinical and molecular analysis of four unrelated Chinese families with pathogenic KLHL40 variants causing nemaline myopathy 8

被引:6
作者
Yuan, Haiming [1 ,2 ]
Wang, Qingming [1 ,2 ]
Zeng, Xiumei [1 ]
He, Peiqing [1 ,2 ]
Xu, Wanfang [1 ]
Guo, Hongmei [1 ]
Liu, Yanhui [1 ,2 ]
Lin, Yangyang [1 ]
机构
[1] Southern Med Univ, Affiliated Dongguan Maternal & Child Hlth Care Ho, Dongguan 523120, Peoples R China
[2] Dongguan Inst Reprod & Genet Res, Dongguan 523120, Peoples R China
关键词
KLHL40; Nemaline myopathy; Polyhydramnios; Fetal akinesia; Respiratory failure; Carrier screening; MUTATIONS;
D O I
10.1186/s13023-022-02306-9
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
Background Homozygous or compound heterozygous variants in the KLHL40 gene cause nemaline myopathy 8 (NEM8), a severe autosomal recessive muscle disorder characterized by prenatal polyhydramnios, fetal akinesia or hypokinesia, joint contractures, fractures, respiratory failure and dysphagia. Currently, 46 individuals with NEM8 have been described in the literature, and 30 variants in KLHL40 have been identified. Results Here, we reported five individuals from four unrelated Chinese families who presented common features of nemaline myopathy and infrequent clinical characteristics. Whole-exome sequencing (WES) was used to identify the causative gene. WES identified a recurrent missense variant c.1516A>C (p.Thr506Pro) and a novel frameshift variant c.543del (p.Ser182Profs*17) in KLHL40 in patient 1, a nonsense variant c.602G>A (p.Trp201*) and a missense variant c.1516A>C (p.Thr506Pro) in KLHL40 in patient 2, and homozygous variant c.1516A>C (p.Thr506Pro) in KLHL40 in patient 3 and both siblings (patients 4 and 5), all of which were confirmed by Sanger sequencing. Next, we estimated the incidence of this disorder in the southern and northern Chinese population to be 4.59/10(6) and 2.95/10(6), respectively, based on the cumulative allele frequency of pathogenic variants in internal database. Conclusion The results of our study expand the mutation spectrum of KLHL40 and enrich our understanding of the clinical characteristics of NEM8. Genetic counseling was provided for the four families involved in this study. Given the severity and the relatively high incidence of this condition, we strongly suggest that KLHL40 be incorporated into a carrier screening panel for the Chinese population.
引用
收藏
页数:7
相关论文
共 13 条
  • [11] Next generation sequencing in a large cohort of patients presenting with neuromuscular disease before or at birth
    Todd, Emily J.
    Yau, Kyle S.
    Ong, Royston
    Slee, Jennie
    McGillivray, George
    Barnett, Christopher P.
    Haliloglu, Goknur
    Talim, Beril
    Akcoren, Zuhal
    Kariminejad, Ariana
    Cairns, Anita
    Clarke, Nigel F.
    Freckmann, Mary-Louise
    Romero, Norma B.
    Williams, Denise
    Sewry, Caroline A.
    Colley, Alison
    Ryan, Monique M.
    Kiraly-Borri, Cathy
    Sivadorai, Padma
    Allcock, Richard J. N.
    Beeson, David
    Maxwell, Susan
    Davis, Mark R.
    Laing, Nigel G.
    Ravenscroft, Gianina
    [J]. ORPHANET JOURNAL OF RARE DISEASES, 2015, 10
  • [12] The KLHL40 c.1516A>C is a Chinese-specific founder mutation causing nemaline myopathy 8: Report of six patients with pre- and postnatal phenotypes
    Yeung, Kit San
    Yu, Florrie N. Y.
    Fung, Cheuk Wing
    Wong, Sheila
    Lee, Hencher C. H.
    Fung, Sharon T. H.
    Fung, Genevieve P. G.
    Leung, Kwok Yin
    Chung, Wai Hang
    Lee, Yun Ting
    Ng, Vivian K. S.
    Yu, Mullin H. C.
    Fung, Jasmine L. F.
    Tsang, Mandy H. Y.
    Chan, Kelvin Y. K.
    Chan, Sophelia H. S.
    Kan, Anita S. Y.
    Chung, Brian H. Y.
    [J]. MOLECULAR GENETICS & GENOMIC MEDICINE, 2020, 8 (07):
  • [13] A novel and recurrent KLHL40 pathogenic variants in a Chinese family of multiple affected neonates with nemaline myopathy 8
    Yi, Sheng
    Zhang, Yue
    Qin, Zailong
    Yi, Shang
    Zheng, Haiyang
    Luo, Jingsi
    Li, Qifei
    Wang, Jin
    Yang, Qi
    Li, Mengting
    Chen, Fei
    Zhang, Qiang
    Zhang, Qinle
    Shen, Yiping
    [J]. MOLECULAR GENETICS & GENOMIC MEDICINE, 2021, 9 (06):